含达雷妥尤单抗的方案治疗mSMART高危多发性骨髓瘤患者的疗效观察  

Efficacy of a Daltuzumab-containing Regimen in Patients with mSMART High-Risk Multiple Myeloma

作　　者：戚振伦 罗雅琴[1,2] 丁淑敏[2] 刘朝霞 QI Zhen-Lun;LUO Ya-Qin;DING Shu-Min;LIU Zhao-Xia(Traditional Chinese Medicine of Shandong University,The Affiliated Hospital of Traditional Chinese Medicine of Shandong University,Jinan 250014,Shandong Province,China;Department of Hematology,The Affiliated Hospital of Traditional Chinese Medicine of Shandong University,Jinan 250014,Shandong Province,China)

机构地区：[1]山东中医药大学,山东济南250014 [2]山东中医药大学附属医院血液科,山东济南250014

出　　处：《中国实验血液学杂志》2024年第3期774-779,共6页Journal of Experimental Hematology

基　　金：国家自然科学基金项目(81704029);齐鲁卫生与健康杰出青年人才资助项目(鲁卫人才字[2020]3号)。

摘　　要：目的:探讨以达雷妥尤单抗为基础的治疗方案在mSMART 3.0评分高危复发难治性多发性骨髓瘤(MM)患者中的疗效与安全性。方法:回顾性收集2020年5月至2023年5月于山东中医药大学附属医院接受治疗的16例mSMART 3.0评分高危复发难治性MM患者的临床资料,患者均接受以达雷妥尤单抗为基础的方案(方案用药包括地塞米松、伊莎佐米、硼替佐米、来那度胺)治疗,分析其疗效和安全性。结果:16例患者的中位年龄为63.5(47-70)岁,其中IgG型10例,IgA型2例,轻链型4例。16例患者均可判断疗效,总体反应率为93.75%(15/16例),其中严格意义的完全缓解(sCR)4例,完全缓解(CR)1例,非常好的部分缓解(VGPR)2例,部分缓解(PR)5例,微小缓解(MR)3例。中位随访期11(2-30)个月,16例患者在中位随访期中位无进展生存期和中位总生存期均未达到。应用以达雷妥尤单抗为基础的治疗方案的血液学不良反应主要为中性粒细胞减少,非血液学不良反应主要为输液相关不良反应及感染。结论:以达雷妥尤单抗为基础的方案治疗mSMART 3.0评分高危的复发难治性MM患者具有较好的疗效及安全性。Objective:To investigate the efficacy and safety of a treatment regimen based on daratumumab in patients with high-risk relapsed refractory multiple myeloma(MM)with mSMART 3.0 score.Methods:Clinical data were collected from 16 patients with mSMART3.0 score high-risk relapsed refractory MM treated at the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from May 2020 to May 2023,all of whom received daltezumab-based regimen(regimen drugs including dexamethasone,isazomib,bortezomib,lenalidomide).The efficacy and safety of the treatment were retrospectively analyzed.Results:The median age of 16 patients was 63.5(47-70)years old,including 10 cases of IgG type,2 cases of IgA type,and 4 cases of light chain type.The curative efficacy was judged in all 16 patients,with an overall response rate of 93.75%(15/16),including 4 cases of strict complete remission(sCR),1 case of complete remission(CR),2 case of very good partial remission(VGPR),partial remission(PR)in 5 cases,and minor remission(MR)in 3 cases.The median follow-up time was 11(2-30)months,and the median progression-free survival and median overall survival were not achieved in 16 patients at the median follow-up period.The hematologic adverse effects of the treatment regimen using daratumumab-based were mainly neutropenia,and the non-hematologic adverse effects were mainly infusion-related adverse reactions and infections.Conclusion:Daratumumab-based regimen for the treatment of relapsed refractory MM patients with high risk of mSMART3.0 score has better efficacy and safety.

关 键 词：达雷妥尤单抗 多发性骨髓瘤 疗效 安全性 

分 类 号：R733.3[医药卫生—肿瘤]